País: Estados Unidos
Idioma: inglés
Fuente: NLM (National Library of Medicine)
ACARBOSE (UNII: T58MSI464G) (ACARBOSE - UNII:T58MSI464G)
Hikma Pharmaceuticals USA Inc.
ACARBOSE
ACARBOSE 25 mg
ORAL
PRESCRIPTION DRUG
Acarbose Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Acarbose Tablets are contraindicated in patients with known hypersensitivity to the drug. Acarbose Tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. Acarbose Tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. In addition, Acarbose Tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.
Acarbose Tablets, USP 25 mg tablets are supplied as round, white to off-white, biconvex tablets, debossed with product identification “54” over “311” on one side and plain on the other side. NDC 0054-0140-25: Bottle of 100 Tablets 50 mg tablets are supplied as round, white to off-white, biconvex tablets, debossed with product identification “54” over “737” on one side and plain on the other side. NDC 0054-0141-25: Bottle of 100 Tablets NDC 0054-0141-20: 10x10 Unit-Dose 100 mg tablets are supplied as round, white to off-white, biconvex tablets, debossed with product identification “54” over “251” on one side and plain on the other side. NDC 0054-0142-25: Bottle of 100 Tablets Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture. For bottles, keep container tightly closed. Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000234/01 Revised February 2023
Abbreviated New Drug Application
ACARBOSE- ACARBOSE TABLET HIKMA PHARMACEUTICALS USA INC. ---------- ACARBOSE TABLETS, USP RX ONLY DESCRIPTION Acarbose Tablets, USP are an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained from fermentation processes of a microorganism, _Actinoplanes utahensis_, and is chemically known as _O_-4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-_O_-α-D-glucopyranosyl-(1→4)-D- glucose. It is a white to off-white powder with a molecular weight of 645.60. Acarbose is soluble in water and has a pK of 5.1. Its molecular formula is C H NO and its chemical structure is as follows: Acarbose Tablets, USP are available for oral administration containing 25 mg, 50 mg or 100 mg acarbose, USP. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose and corn starch. CLINICAL PHARMACOLOGY Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, acarbose reduces a 25 43 18 levels of glycosylated hemoglobin in patients with type 2 diabetes mellitus. Systemic non- enzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. MECHANISM OF ACTION In contrast to sulfonylureas, acarbose does not enhance insulin secretion. The antihyperglycemic action of acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, while the membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides i Leer el documento completo